# Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)

> **NCT02106832** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 521 (actual)

## Conditions studied

- Bronchiectasis

## Interventions

- **DRUG:** Ciprofloxacin (BAYQ3939) dry powder for inhalation
- **DRUG:** Ciprofloxacin (BAYQ3939) dry powder for inhalation
- **DRUG:** Placebo
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02106832
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04-30
- **Primary completion:** 2016-09-13
- **Final completion:** 2016-10-19
- **Target enrollment:** 521 (ACTUAL)
- **Last updated:** 2017-10-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02106832

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02106832, "Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02106832. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*